Europe Cell Expansion Market Report

Europe Cell Expansion Market Size

In 2024, the Europe Cell Expansion Market was valued at USD 4.11 billion and is forecasted to grow to USD 18.64 billion by 2033, at a CAGR of 18.3%.

Cellular expansion is the large-scale artificial manufacturing of daughter cells from a single cell to support clinical studies. The regenerative medicinal drug enables the body to shape new functional tissue to replace faulty or lost tissue, allowing for inadequate healing procedures. Cell enlargement is currently broadly used to enhance transplantation and treat various diseases such as rheumatoid arthritis, diabetes, etc. The growing demand for regenerative drugs offering faster outcomes and cellular-based treatment plans with too many affected persons compatibility is anticipated to boost the cellular expansion market.

The outstanding factors contributing to the cell expansion market are the growing number of GMP-certified manufacturing facilities, increasing investment by the authority for research, developing pervasiveness of recurrent diseases, and increased cell-based products and therapy expenses 3D cellular growth method. The increasing occurrence of chronic medical conditions is expected to promote the European cell expansion market over the forecast duration.

The constraints faced by the expansion of the cell expansion market include a skilled workforce and high-tech instrumentation. Ethical issues regarding cell biology studies, a high value of cellular-based research, and strict recommendations are some of the factors that could hamper the market growth.

Geographically, the European cell expansion market holds the second position in terms of percentage globally. Due to several untapped markets linked with the growing number of recurring illnesses, there may be market growth in the region. Growing personal quarter investments through key businesses to grow R&D to expand marketplace margins will enhance market growth within the European region.

KEY MARKET PLAYERS

Some of the prominent companies leading the Europe cell expansion market profiled in the report include Beckman Coulter, Inc. (U.S.), Becton, Dickinson, and Company (U.S.), Corning, Inc. (U.S.), GE Healthcare (U.K.), Lonza (Switzerland), Merck KGaA (Germany), Miltenyi Biotec (Germany), STEMCELL Technologies, Inc. (Canada), Terumo BCT, Inc. (U.S.), and Thermo Fisher Scientific, Inc. (U.S.)

RECENT MARKET HAPPENINGS

• In 2020, Danaher acquired the Biopharma business from General Electric Company's Life Sciences division to form a new division called Cytiva and act as a standalone operating company within Danaher's Life Sciences division.
• In 2020, Applikon Biotechnology partnered with Sotelab to strengthen South America's advanced cultivation systems market.
• In 2019, Thermo Fisher Scientific invested around USD 24 million in its Inchinnan, Scotland site to expand global bio-production capabilities with additional large-volume liquid manufacturing capacity for cell culture media to meet growing customer demand.

MARKET SEGMENTATION

This market research report on the Europe Cell Expansion Market has been segmented and sub-segmented into the following categories

By Product

• Instruments
• Consumables
• Disposables

By Cell Type

• Human Cells
  • Human Differentiated Stem Cells
  • Human Stem Cells
    • Embryonic stem cells
    • Adult Stem Cells
• Animal Stem Cells

By Application

• Regenerative Medicine
• Stem Cell Research
• Cancer
• Cell-Based Research

By End User

• Hospitals
• Biotech and Pharma Companies
• Academic and Research Institutes

By Country

• UK
• France
• Spain
• Germany
• Italy
• Russia
• Sweden
• Denmark
• Switzerland
• Netherlands
• Turkey
• Czech Republic
• Rest of Europe